Charles River Laboratories to purchase Celsis International for US$212m

Expanding the company's endotoxin and microbial detection systems

Charles River Laboratories is set to buy quality control testing firm Celsis International, with US headquarters in Chicago, for US$212m in cash, expanding its endotoxin and microbial detection (EMD) systems. Celsis’s systems are used mainly for product-release testing to help ensure the safe manufacture of drugs and consumer products.

The addition of Celsis' Advance II, Accel, and Innovate systems for non-sterile applications, will complement Charles River's PTS-Micro, a rapid bioburden detection system for sterile biopharmaceutical applications.

Charles River's Chief Executive James Foster said the acquisition will establish the company as a comprehensive provider of rapid quality control testing solutions across multiple industries.

'The transaction nearly doubles the market opportunity for EMD testing products and services, offering access to the consumer products market in addition to our core biopharmaceutical market,' he said.

The transaction is expected to close in this year's third quarter, subject to customary closing conditions.

Companies